Jump Trading Llc increased Jpmorgan Chase & Co (Put) (JPM) stake by 12.66% reported in 2018Q4 SEC filing. Jump Trading Llc acquired 8,100 shares as Jpmorgan Chase & Co (Put) (JPM)’s stock declined 6.08%. The Jump Trading Llc holds 72,100 shares with $7.04 million value, up from 64,000 last quarter. Jpmorgan Chase & Co (Put) now has $340.50B valuation. The stock decreased 0.37% or $0.39 during the last trading session, reaching $103.96. About 4.07 million shares traded. JPMorgan Chase & Co. (NYSE:JPM) has declined 8.15% since March 12, 2018 and is downtrending. It has underperformed by 12.52% the S&P500. Some Historical JPM News: 26/03/2018 – J.P. Morgan customers will now be able to ask Alexa for the firm’s research reports, according to a report; 14/05/2018 – JPMORGAN SEEKS MAJORITY STAKE IN CHINA FUND MANAGEMENT JV; 18/05/2018 – GRIFOLS GRLS.MC : JP MORGAN RAISES TARGET PRICE TO 27 EUROS FROM 25.5 EUROS; 06/03/2018 – Kennametal To Attend J.P. Morgan Aviation, Transportation & Industrials Conference On March 13, 2018; 03/04/2018 – MEDIA-JPMorgan targets $250 mln for special situations- Bloomberg; 09/05/2018 – WWE Presenting at JPMorgan Conference May 15; 04/04/2018 – JPMORGAN ESTATE ACCORD INVOLVES SOME, NOT ALL FAMILY MEMBERS; 09/05/2018 – Stanley Black Presenting at JPMorgan Conference May 15; 14/05/2018 – AMD Presenting at JPMorgan Conference Tomorrow; 04/05/2018 – JPMORGAN GLOBAL APRIL COMPOSITE PMI AT 53.8 VS 53.3 LAST MONTH
The stock of InflaRx N.V. (NASDAQ:IFRX) reached all time high today, Mar, 12 and still has $51.96 target or 6.00% above today’s $49.02 share price. This indicates more upside for the $1.26B company. This technical setup was reported by Barchart.com. If the $51.96 PT is reached, the company will be worth $75.48 million more. The stock increased 0.84% or $0.41 during the last trading session, reaching $49.02. About 220,933 shares traded or 114.39% up from the average. InflaRx N.V. (NASDAQ:IFRX) has risen 39.39% since March 12, 2018 and is uptrending. It has outperformed by 35.02% the S&P500. Some Historical IFRX News: 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018; 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE
Among 8 analysts covering JPMorgan Chase (NYSE:JPM), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. JPMorgan Chase had 12 analyst reports since September 17, 2018 according to SRatingsIntel. Credit Suisse maintained JPMorgan Chase & Co. (NYSE:JPM) on Friday, December 7 with “Outperform” rating. The stock has “Outperform” rating by Wells Fargo on Thursday, February 14. The rating was downgraded by Jefferies on Tuesday, January 8 to “Hold”. The rating was maintained by BMO Capital Markets on Wednesday, January 16 with “Market Perform”. Bank of America maintained JPMorgan Chase & Co. (NYSE:JPM) rating on Monday, September 17. Bank of America has “Buy” rating and $132 target. Morgan Stanley maintained JPMorgan Chase & Co. (NYSE:JPM) on Tuesday, January 8 with “Overweight” rating. Citigroup maintained it with “Neutral” rating and $125 target in Wednesday, September 26 report. BMO Capital Markets maintained JPMorgan Chase & Co. (NYSE:JPM) rating on Thursday, February 28. BMO Capital Markets has “Market Perform” rating and $116 target. Barclays Capital maintained JPMorgan Chase & Co. (NYSE:JPM) rating on Thursday, February 21. Barclays Capital has “Buy” rating and $140 target. Morgan Stanley maintained the stock with “Buy” rating in Wednesday, February 27 report.
Jump Trading Llc decreased Baidu Inc (NASDAQ:BIDU) stake by 4,400 shares to 100 valued at $16,000 in 2018Q4. It also reduced Ishares Inc (Call) (EWZ) stake by 44,100 shares and now owns 52,400 shares. Twitter Inc (Put) (NYSE:TWTR) was reduced too.
Since October 19, 2018, it had 2 buys, and 5 sales for $4.86 million activity. Beer Lori A sold $1.40 million worth of stock or 13,341 shares. BACON ASHLEY also sold $599,304 worth of JPMorgan Chase & Co. (NYSE:JPM) on Sunday, January 13. The insider Scher Peter sold 18,679 shares worth $1.96 million. 1,150 shares were bought by HOBSON MELLODY L, worth $125,281. Petno Douglas B had sold 11,659 shares worth $1.22 million on Tuesday, January 29. CROWN JAMES S had bought 5,000 shares worth $518,950 on Tuesday, February 5. Friedman Stacey also sold $317,310 worth of JPMorgan Chase & Co. (NYSE:JPM) on Tuesday, January 29.
More notable recent JPMorgan Chase & Co. (NYSE:JPM) news were published by: Seekingalpha.com which released: “JPMorgan adds to BetaBuilders ETF line – Seeking Alpha” on March 11, 2019, also Bizjournals.com with their article: “JPMorgan Chase ups its game to court Bay Area startups – San Francisco Business Times” published on March 11, 2019, Nasdaq.com published: “3 Top Bank Stocks to Buy Right Now – Nasdaq” on March 10, 2019. More interesting news about JPMorgan Chase & Co. (NYSE:JPM) were released by: Benzinga.com and their article: “J P Morgan Chase & Co (NYSE:JPM) – What To Consider Watching In March: Tariffs, Fed, Oil – Benzinga” published on March 01, 2019 as well as Seekingalpha.com‘s news article titled: “JPMorgan: Buy Or Sell? – Seeking Alpha” with publication date: February 25, 2019.
Investors sentiment increased to 1 in 2018 Q4. Its up 0.05, from 0.95 in 2018Q3. It increased, as 71 investors sold JPM shares while 735 reduced holdings. 135 funds opened positions while 667 raised stakes. 2.33 billion shares or 0.45% more from 2.32 billion shares in 2018Q3 were reported. Institute For Wealth Mngmt Ltd Liability Corporation holds 1.1% in JPMorgan Chase & Co. (NYSE:JPM) or 27,429 shares. Loomis Sayles & LP invested in 0.01% or 63,309 shares. Sageworth Com stated it has 0.01% in JPMorgan Chase & Co. (NYSE:JPM). Westwood Hldg Group holds 2.21% or 1.98 million shares in its portfolio. Clearbridge Investments Llc invested 0.68% of its portfolio in JPMorgan Chase & Co. (NYSE:JPM). Virginia-based Heritage Wealth Advisors has invested 0.1% in JPMorgan Chase & Co. (NYSE:JPM). Camelot Portfolios Limited Co stated it has 3,237 shares or 0.15% of all its holdings. Kidder Stephen W invested in 0.15% or 3,600 shares. New York-based Forte Capital Limited Company Adv has invested 0.77% in JPMorgan Chase & Co. (NYSE:JPM). Tru Com Of Virginia Va owns 92,720 shares or 1.33% of their US portfolio. Addenda stated it has 65,121 shares or 0.56% of all its holdings. Cibc Asset Inc invested 0.34% of its portfolio in JPMorgan Chase & Co. (NYSE:JPM). Bailard Inc stated it has 89,044 shares or 0.59% of all its holdings. Culbertson A N Com Inc invested in 3.68% or 118,462 shares. Karpus Mngmt Inc holds 0.01% or 2,109 shares.
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Globenewswire.com which released: “Richard Brudnick to Join InflaRx Board of Directors – GlobeNewswire” on February 14, 2019, also Nasdaq.com with their article: “ING publishes proxy materials for 2019 AGM – Nasdaq” published on March 12, 2019, Nasdaq.com published: “Biophytis Reports Annual 2018 Financial Results and Provides Operational Update – Nasdaq” on March 12, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Streetinsider.com and their article: “InflaRx NV (IFRX) Granted Approval to Begin Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum – StreetInsider.com” published on February 27, 2019 as well as Nasdaq.com‘s news article titled: “Endeavour Announces Board Change – Nasdaq” with publication date: March 11, 2019.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $1.26 billion. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.
Analysts await InflaRx N.V. (NASDAQ:IFRX) to report earnings on April, 4. After $-0.31 actual EPS reported by InflaRx N.V. for the previous quarter, Wall Street now forecasts 41.94% negative EPS growth.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.